GlassScriptPhysician profile
Timothy Choy
NPI 1033739560
$4,912.59
in general payments reported to CMS, 2019-2025
25 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $575 · 2024: $2,529 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,912.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $521.80 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $507.38 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $487.36 | 2023-2025 | |
| Lilly USA, LLC | $458.51 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $407.85 | 2023-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $407.63 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $337.11 | 2023-2025 | |
| Exact Sciences Corporation | $287.89 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $261.29 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $244.42 | 2024-2025 | Evenity, Prolia, Otezla |
| Lundbeck LLC | $176.82 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $164.05 | 2024-2025 | Auvelity, Symbravo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.14 | 2023-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $94.59 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $94.29 | 2023-2024 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.41 | 2024-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.54 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $51.33 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.31 | 2023-2025 | Xifaxan, Trulance |
| Corium, LLC | $32.86 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $24.57 | 2025 | Gemtesa |
| Lexicon Pharmaceuticals, INC. | $23.00 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $22.47 | 2023 | Spravato |
| Dynavax Technologies Corporation | $17.17 | 2024 | Heplisav-B |
| Currax Pharmaceuticals LLC | $13.80 | 2023 | Nexletol, Onzetra Xsail, Nexlizet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.